CADL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):
Our systems believe the stock currently is overvalued by 0.09% compare to its pairs and should correct downwards.

Stats
Dagens volum	999 743
Gjennomsnittsvolum	5.44M
Markedsverdi	264.71M
EPS	$-0.290 ( 2023-11-09 )
Neste inntjeningsdato	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.89
ATR14	$0.0330 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	25 000	Stock Option (Right to Buy)
2024-01-12	Schoch Charles	Sell	39 498	Stock Option (Right to Buy)
2023-11-28	Tyagarajan Seshu	Sell	17 328	Common Stock

INSIDER POWER
76.72
Last 92 transactions
Buy: 8 106 969 \| Sell: 4 393 086

Korrelasjon (AI algo v.1.1b): Overvalued: -0.09% $9.19 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.05 (neutral)

Kort: 0.45 (neutral)

Signal:(33.833) Neutral

Candel Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
SCTL	0.94
MESO	0.938
LABP	0.929
SMTC	0.925
MOTNU	0.923
NN	0.918
QRHC	0.916
PAYS	0.916
STOK	0.915
SRTS	0.913

10 Mest negative korrelasjoner
ATHN	-0.936
PTRA	-0.923
ARIZ	-0.92
AEY	-0.902
LUCD	-0.895
ONEM	-0.89
EZGO	-0.89
LULU	-0.886
SFT	-0.881
AFYA	-0.878

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Candel Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.33
( neutral )

0.43
( neutral )

0.00
( neutral )

0.38
( neutral )

0.24
( neutral )

Candel Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2023
Omsetning:	$0
Bruttogevinst:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2022
Omsetning:	$125 000
Bruttogevinst:	$-862 000 (-689.60 %)
EPS:	$-0.0994

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.934

Financial Reports:

No articles found.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Sanntidsoppdatering for Candel Therapeutics, Inc. [CADL]

Upcoming Earnings Alert